MARKET WIREReuters • 3h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why LAB Stock advanced +0.49% Today — RQD Quant Desk Flash
$0.62 +0.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.62
Standard BioTools Inc. (LAB) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $244.7M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.62 (-0.10%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-8.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LAB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY LAB SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (37% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (32% of score)
FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 37.8 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$0.69-8.7% Next Q
49
Q2 (-2Q)Grade D$0.63-3.2% Next Q
46
Q3 (-1Q)Grade D$0.61+1.6% Next Q
44
CurrentGrade D-$0.62-7.2% Hist 90D α
41
Trajectory: D (49) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a LAB Turnaround Squeeze
While LAB currently carries a cautious 41/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Big institutional funds and options desks are actively positioning on the bullish side.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.68) and Max Pain ($0.65) forces dealer call-delta covering toward $1.81.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $LAB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LAB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why LAB Stock advanced +0.49% Today — RQD Quant Desk Flash
Standard BioTools Inc. (LAB) advanced +0.49% to $0.62, trading at 3% of its 52-week range ($0.59 – $1.72). Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($0.59 – $1.72) with RSI-14 at 37.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.62 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 49.9% gross margin and $0 annual free cash flow.
Live LAB Headlines & Catalysts
MARKET WIRECNBC • 5h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 5h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 6h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 8h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 8h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 9h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 10h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LAB)
- ✓Walkthrough of LAB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
LAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.33%🛡️ HOLDING TREND SUPPORT
2026-10-30O $0.62H $0.62L $0.60C $0.62VOL 1.00M
RES: $0.75SUP: $0.59SMA50: $0.68SMA200: $0.92
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -6.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on LAB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for LAB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LAB)
Health Care Rank #612 of 1016
⚔️ NAUT vs LAB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (LAB vs. NAUT, QTRX, SEER, CTKB)
Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Standard BioTools Inc. (LAB) ranks #612 by composite RQD confidence (41/100, grade D-) and #553 by equity capitalization ($244.7M). Within this direct 5-issuer industry benchmark cohort, LAB leads on earnings valuation at N/A trailing P/E, while CTKB leads on capital efficiency and profitability with -12.7% ROIC and 51.8% gross margin. LAB currently leads its immediate peer cohort in composite quantitative strength at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LAB
ACTIVE
Standard BioTools Inc. | D- | 41/100 | — | 49.9% | -28.7% | +0.49% | $244.7M | Benchmark Subject |
| NAUT Nautilus Biotechnology Inc. | D- | 41/100 | — | — | -35.0% | -2.18% | $399.9M | /naut-vs-lab → |
| QTRX Quanterix Corporation | E | 28/100 | — | 46.8% | -35.0% | +0.80% | $148.7M | /qtrx-vs-lab → |
| SEER Seer Inc. (Class A) | E | 30/100 | — | 51.1% | -29.1% | -2.51% | $107.4M | /seer-vs-lab → |
| CTKB Cytek Biosciences Inc. | D- | 41/100 | — | 51.8% | -12.7% | +2.61% | $818.9M | /ctkb-vs-lab → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001162194In its most recent audited fiscal period (FY2025, filed 2025-12-31), Standard BioTools Inc. (LAB) reported GAAP revenue of $85.3M (-6.2% vs. FY2024 revenue of $91.0M , and -19.8% cumulative change since FY2023) , GAAP net income of -$74.9M, operating cash flow of -$74.3M, and free cash flow of -$82.6M (+45.6% YoY). On the balance sheet, LAB closed FY2025 with $567.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $85.3M | -$74.9M | -$74.3M | -$82.6M | $567.8M | — |
| FY2024 (FY) | 2024-12-31 | $91.0M | -$138.9M | -$143.5M | -$151.8M | $612.3M | — |
| FY2023 (FY) | 2023-12-31 | $106.3M | -$74.7M | -$43.3M | -$43.3M | — | — |
3. LAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs LAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Standard BioTools Inc. (NASDAQ: LAB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.62 (+0.49% 1D, market cap $244.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LAB ranks #612 in composite RQD confidence.
How does LAB compare to NAUT and QTRX in the Health Care sector?
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), LAB carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 49.9%, and ROIC of -28.7%. By comparison, NAUT (Nautilus Biotechnology Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $399.9M) and QTRX (Quanterix Corporation) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $148.7M). Among the 5-stock peer group, LAB leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for LAB?
Per LAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001162194), Standard BioTools Inc. generated $85.3M in revenue (-6.2% YoY), -$74.9M in net income, and -$82.6M in free cash flow against $567.8M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is LAB trading relative to its 50-day, 200-day, and 52-week technical levels?
LAB last traded at $0.62 (+0.49% on volume of 445,806 shares), positioning the stock -8.82% below its 50-day simple moving average ($0.68) and -32.61% below its 200-day simple moving average ($0.92). Across its 52-week range of $0.59 to $1.72, LAB sits at the 2.7% percentile with a 14-day RSI of 37.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.70).
LAB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is LAB stock moving today?
Why LAB Stock advanced +0.49% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.